Aquestive Therapeutics, Inc. Q3 2025 Earnings Recap

AQST Q3 2025 November 6, 2025

Get alerts when AQST reports next quarter

Aquestive Therapeutics demonstrated strong momentum heading into its Q3 2025 earnings, highlighted by increased awareness of its Anaphylm dibutepinephrine Sublingual Film program and preparations for a potential FDA approval.

Earnings Per Share Miss

$-0.14 vs $-0.11 est.

-27.3% surprise

Revenue Miss

12807000 vs 12943500 est.

-1.1% surprise

Market Reaction

1-Day +2.17%

5-Day -5.17%

30-Day +3.33%

See AQST alongside your other holdings

Add to your portfolio — free

Key Takeaways

Nearly 25% of allergists have engaged with Aquestive's CME training, enhancing awareness of Anaphylm ahead of the FDA review due by January 31, 2026.
Strategic prelaunch activities for Anaphylm are on track, with marketing materials finalized and a supply chain ready for rapid production upon FDA approval.
Leadership restructuring aims to bolster efforts in both the Anaphylm launch and the Adrenaverse platform, including the appointment of Dr. Matthew Davis as Chief Development Officer.
The company anticipates initiating clinical trials for its AQST-108 program in January 2026, further expanding its product pipeline.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit AQST on AllInvestView.

Previous Q2 2025